First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study.
To assess outcomes in patients treated with first-line bevacizumab-containing therapy for human epidermal growth factor receptor (HER)2-negative metastatic breast cancer (mBC) at a single centre with a homogenous standard-of-care.



Information on patient and disease characteristics, efficacy, and safety was extracted from computer-based records of all patients receiving first-line bevacizumab-paclitaxel at the Curie Institute, Paris, France, between 2008 and 2011.



Median progression-free survival in the 116 treated patients was 13.2 months; median overall survival was 38.4 months. Corresponding values were 9.0 and 18.8 months, respectively, in patients with triple-negative mBC, and 19.4 and 58.8 months, respectively, in patients receiving maintenance endocrine therapy. No new safety signals were seen.



Outcomes in patients treated with bevacizumab-paclitaxel at our center were consistent with efficacy in prospective clinical trials, with notable activity in poor-prognosis disease. Maintenance endocrine or oral therapy with bevacizumab after paclitaxel discontinuation was associated with long-term disease control.
Department of Medical Oncology, Curie Institute, PSL Research University, Paris, France veronique.dieras@curie.fr.
Veronique
V
Dieras
Department of Medical Oncology, Curie Institute, PSL Research University, Paris, France.
Simona
S
Pop
Biostatistics Unit, Curie Institute, PSL Research University, Paris, France.|INSERM U900, Curie Institute, PSL Research University, Paris, France.
Frederique
F
Berger
Biostatistics Unit, Curie Institute, PSL Research University, Paris, France.
Marie-Eglantine
ME
Dujaric
Department of Medical Oncology, Curie Institute, PSL Research University, Paris, France.
Philippe
P
Beuzeboc
Pharmacy Department, Curie Institute, PSL Research University, Paris, France.
Laurence
L
Escalup
Department of Medical Oncology, Curie Institute, PSL Research University, Paris, France.|INSERM U900, Curie Institute, PSL Research University, Paris, France.
François Clement
FC
Bidard
Department of Medical Oncology, Curie Institute, PSL Research University, Paris, France.
Paul Henri
PH
Cottu
Department of Medical Oncology, Curie Institute, PSL Research University, Paris, France.
Christophe
C
LE Tourneau
Department of Medical Oncology, Curie Institute, PSL Research University, Paris, France.
Sophie
S
Piperno-Neumann
Department of Medical Oncology, Curie Institute, PSL Research University, Paris, France.
Valerie
V
Laurence
Biostatistics Unit, Curie Institute, PSL Research University, Paris, France.
Mathieu
M
Robain
Biostatistics Unit, Curie Institute, PSL Research University, Paris, France.
Bernard
B
Asselain
Department of Medical Oncology, Curie Institute, PSL Research University, Paris, France.|Descartes University Paris, Paris, France.
Jean-Yves
JY
Pierga
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D018572:Disease-Free Survival; D005260:Female; D005602:France; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D017239:Paclitaxel / Q000008:administration & dosage*; D011379:Prognosis; D011446:Prospective Studies; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D012189:Retrospective Studies; D016896:Treatment Outcome; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism*
D000068258:Bevacizumab; D017239:Paclitaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human
Bevacizumab; HER2-negative; first-line; metastatic breast cancer; paclitaxel